At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 35 enrolled
Drug / intervention
Olanzapinedrug
Likely dose
Olanzapine 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
In Brief
A Phase 4 clinical trial evaluating Olanzapine for Healthy. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The primary aim of this study is to investigate antipsychotic drug effects on healthy brain metabolism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartNov 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedSep 1, 2015
Enrollment StartNov 17, 2017
Primary CompletionNov 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago
Interventions
Olanzapinedrug
All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).